In the past 52-week period, shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) have moved within the range of $3.50 to $8.30. On the stock’s most recent trading day, the company’s shares ended the regular session at $5.67, which is 31.69% higher than its 52-week high.
TherapeuticsMD, Inc. (TXMD) has demonstrated a 20-day simple moving average (SMA) of 14.72%, and a 50-day SMA of 3.70%. This public company’s current market capitalization stands at $1.21 billion.Analyzing Consensus Estimates, Sales Revenue and Net Income
When thinking about buying shares in a public company, it is useful to gauge the average enthusiasm level of Wall Street analysts for that specific stock. According to the latest data, the consensus recommendation for TherapeuticsMD, Inc. (TXMD) is Outperform.
When it comes to quarterly financial results, publicly-traded companies usually post earnings and revenue figures that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, TherapeuticsMD, Inc. (TXMD) delivered a 15.35% surprise with its net revenue.
Meanwhile, during the same quarter TherapeuticsMD, Inc. (TXMD) delivered a -35.66% earnings surprise. Net earnings for the quarter were posted at -$0.07 per share, whereas Wall Street had forecast -$0.11 per share.Ownership at TherapeuticsMD, Inc. (TXMD), According to Most Recent SEC Filings
Investors can gain useful insight on institutional ownership within a public company by taking a look at the organization’s most recent 13F filings. TherapeuticsMD, Inc. (TXMD) has 0 billion shares outstanding currently, 76.13% of which belong to institutional investors. Those institutional holdings amount to $0.93 billion.
Additionally, according to the most recent 13F filing from TherapeuticsMD, Inc. (TXMD), there were 12 new positions totaling 410,449 shares of the company’s stock. There were 19 sold out positions, on the other hand, totaling 5,950,490 shares.Short, Medium and Long Term Indicators
By looking at a stock’s average trade volume – in the short, medium, and long terms – we can gain a better understanding of investor sentiment and trading activity. TherapeuticsMD, Inc. (TXMD) has had a 20-day average volume of 4,236,690 shares, with an average of 40% of short term indicators pointed at Buy.
The stock’s 50-day average volume has been 3,428,346 shares, with an average of 25% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 2,977,120 shares with 0% of long-term indicators pointing to Hold.